Resistance of Targeted Therapies Excluding Antibodies for Lymphomas, Hardcover

Resistance to targeted therapies is a major challenge in the treatment of lymphomas. This comprehensive hardcover book explores the various mechanisms of resistance to targeted therapies in lymphomas, focusing on non-antibody treatments. The book covers the latest research on resistance mechanisms such as genetic mutations, signaling pathway alterations, and immune system evasion. It also discusses strategies to overcome resistance, including combination therapies, novel drug targets, and personalized medicine approaches. Key features of this book include: - In-depth coverage of resistance mechanisms to targeted therapies in lymphomas - Discussion of novel treatment strategies to overcome resistance - Detailed case studies and clinical trials - Contributions from leading experts in the field This book is essential reading for oncologists, hematologists, researchers, and students interested in understanding and overcoming resistance to targeted therapies in lymphomas. It provides valuable insights into the challenges and opportunities in this rapidly evolving field of cancer treatment.